Aclaris Therapeutics Inc (NASDAQ:ACRS) Shorts Reduced By 4.86% As Of Apr 17, 2018

April 17, 2018 - By Michele Cranor

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Corporate Logo

Aclaris Therapeutics Inc (NASDAQ:ACRS) had a decrease of its short interest by 4.86%. FINRA issued short interest of ACRS’s total 5.01M shares. The 5.27 million previous shares are down with 4.86%. Aclaris Therapeutics Inc (NASDAQ:ACRS) has 290,300 shares average volume. It’ll cost 17 days for ACRS to recover its former position. Float short on Aclaris Therapeutics Inc is 19.8%.

On during the last trading session the stock increased $0.16 or 0.91%, reaching $17.78.Aclaris Therapeutics, Inc. has volume of 183,844 shares. Since April 17, 2017 ACRS has declined 45.27% and is downtrending. ACRS underperformed by 56.82% the S&P 500.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology.The firm is valued at $549.43 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor.Last it reported negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: